PDF(Pubmed)
Abstract：
The potential infection of cellular therapies by SARS-CoV-2 present high risks, as the target patients for these treatments are often immunocompromised or have chronic diseases associated with a higher risk of serious illness and death by COVID-19. The multicellular tropism of this virus presents challenges for the manufacturing of cell therapies, whereby the material could potentially become infected at the source or during cell processing. In this review we assess the risk of a SARS-CoV-2 propagation in cell types used to date in cellular therapies. Altogether, the risk of SARS-CoV-2 contamination of cellular products remains low. This risk should be evaluated on an individual basis, considering ACE2 and TMPRSS2 expression, existing literature regarding the susceptibility to infection, and single cell RNA sequencing data of COVID-19 patients. This analysis should ideally be performed for both the cells being manufactured and the cells used to produce the vector to ensure patient safety.
Cell therapies are medicines based on the utilization of different cell types that are manufactured in special facilities. SARS-CoV-2, the virus that causes COVID-19, can infect a wide range of cell types. Patients requiring a cell therapy may be at higher risk of severe COVID-19 due to their underlying medical conditions. In this context, it is of importance to evaluate the risk of a SARS-CoV-2 contamination during the production of cell therapies to avoid possible infections. In this review, the authors assess the risk of an infection for cells being used as therapies to date and propose a systematic way to evaluate this risk.
Cell therapies are medicines based on the utilization of different cell types that are manufactured in special facilities. SARS-CoV-2, the virus that causes COVID-19, can infect a wide range of cell types. Patients requiring a cell therapy may be at higher risk of severe COVID-19 due to their underlying medical conditions. In this context, it is of importance to evaluate the risk of a SARS-CoV-2 contamination during the production of cell therapies to avoid possible infections. In this review, the authors assess the risk of an infection for cells being used as therapies to date and propose a systematic way to evaluate this risk.
摘要：
SARS-CoV-2对细胞疗法的潜在感染存在高风险，因为这些治疗的目标患者通常免疫功能低下或患有与COVID-19引起的严重疾病和死亡风险较高相关的慢性疾病。这种病毒的多细胞嗜性对细胞疗法的制造提出了挑战，由此材料可能在来源处或在细胞处理期间被感染。在这篇综述中，我们评估了迄今为止用于细胞疗法的细胞类型中SARS-CoV-2传播的风险。总之,SARS-CoV-2污染细胞产物的风险仍然很低。这种风险应该在个人基础上进行评估，考虑ACE2和TMPRSS2表达，关于感染易感性的现有文献，和COVID-19患者的单细胞RNA测序数据。该分析应理想地对正在制造的细胞和用于产生载体的细胞进行,以确保患者安全。
细胞疗法是基于在特殊设施中制造的不同细胞类型的利用的药物。SARS-CoV-2是导致COVID-19的病毒，可以感染多种细胞类型。由于潜在的医疗状况，需要细胞治疗的患者可能面临更高的严重COVID-19风险。在这种情况下，评估细胞疗法生产过程中SARS-CoV-2污染的风险以避免可能的感染是很重要的.在这次审查中,作者评估了迄今为止被用作治疗的细胞感染的风险,并提出了一种系统的方法来评估这种风险.
细胞疗法是基于在特殊设施中制造的不同细胞类型的利用的药物。SARS-CoV-2是导致COVID-19的病毒，可以感染多种细胞类型。由于潜在的医疗状况，需要细胞治疗的患者可能面临更高的严重COVID-19风险。在这种情况下，评估细胞疗法生产过程中SARS-CoV-2污染的风险以避免可能的感染是很重要的.在这次审查中,作者评估了迄今为止被用作治疗的细胞感染的风险,并提出了一种系统的方法来评估这种风险.
